Showing 301 - 320 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((i.e decrease) OR (a decrease)) ))', query time: 0.53s Refine Results
  1. 301
  2. 302
  3. 303
  4. 304
  5. 305
  6. 306
  7. 307
  8. 308
  9. 309
  10. 310
  11. 311

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  12. 312
  13. 313

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 314

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  15. 315

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  16. 316
  17. 317

    Supplementary Material for: Allopurinol Use is Associated With Decreased Incidence of Hepatic Decompensation and Overall Mortality Among Individuals With Cirrhosis: a Propensity-ma... by figshare admin karger (2628495)

    Published 2025
    “…Conclusion: In a propensity-score matched analysis of a large national database, individuals with cirrhosis and allopurinol use had significantly lower risk of hepatic decompensation and overall mortality. …”
  18. 318
  19. 319

    Metabolites with decreasing levels during the development. by Martin Sládek (130663)

    Published 2025
    “…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”
  20. 320